Robin Jackman, Ph.D., is CEO and a co-founder of January Therapeutics. He has over 20 years of experience at the intersection of medicine, science, and business. Previously, he led the venture-backed orphan drug startup Zacharon Pharmaceuticals from discovery stage through large pharma partnerships and an eventual sale to BioMarin. Prior to that, he headed the oncology business division at Vical, advancing 2 immuno-oncology biologics through a Phase 1 clinical trial and a Phase 3, worldwide 125-site clinical trial respectively. Robin also led a biopharma company in critical care medicine from concept-stage through full CMC development, IND filings and into Phase 2 clinical efficacy trials. Dr. Jackman is expert at building and advancing new programs and platforms; drug discovery to clinical development and partnerships. In his career he has completed over $10 billion in deal value through 80+ partnerships, financings, and company sales. Robin holds graduate degrees from Harvard Medical School and Harvard University, and an undergraduate degree from Stanford University.
Dr. Raheja is Chief Scientific Officer and a co-founder of January Therapeutics. He has 20 years of medicinal chemistry and drug discovery experience; having worked previously for Celgene, Pfizer, and Ontogen Therapeutics. Dr. Raheja has worked in multiple therapeutic areas including oncology, inflammation, neuroscience, dermatology, and antivirals. He has delivered 10 development candidates as a project leader or from within his organizations, with multiple compounds reaching Phase 2 clinical trials. Dr. Raheja is an inventor on 4 compounds currently in clinical trials or in late stage development in oncology and inflammatory disease. He previously founded Integrated Pharma Solutions, an independent drug discovery company. Dr. Raheja completed his post-doctoral training at University of Pennsylvania under the direction of the late Ralph Hirschmann and Amos B. Smith III, and his Ph.D. at Wayne State University.
President Research & Development, Founder
Jason Kahana is co-founder and President, Research and Development at January Therapeutics. He has 18 years of experience specializing in discovery and pharmacology for small/large molecules in oncology. His experience includes directing oncology research efforts at GlaxoSmithKline, Merck, Takeda Pharmaceutical, and Celgene. Jason has managed all phases of preclinical development ranging from target identification/validation to development candidate/IND filing; ultimately resulting in 3 compounds reaching human clinical trials. Previously he also founded Integrity BioSolutions, a San Diego-based biotechnology drug discovery and development company with reagents, cell lines, and instrumentation for the bioprocess industry. Jason received his B.A. in Mathematics from Northwestern University and a Ph.D. in Cellular and Developmental Biology from Harvard Medical School, with postdoctoral training at the Ludwig Institute for Cancer Research. He also serves on the National Cancer Institute’s Experimental Therapeutics section.
11575 Sorrento Valley Rd., Suite 200
San Diego, CA 92121